QuidelOrtho reports Q4 adjusted EPS $1.76, consensus $1.43

Reports Q4 revenue $866.5M, consensus $779.58M. "Led by ex-COVID-19 growth in Point of Care, Molecular Diagnostics and Transfusion Medicine, we ended a milestone year for QuidelOrtho with an outstanding performance in the fourth quarter even as our largest and generally most resilient business unit, Labs, faced lockdowns in China and continued supply chain challenges," said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho. "The fourth quarter further reflects the powerful mix of hard work, focus and dedication we’ve seen from our entire QuidelOrtho team throughout 2022. Time and again, our teams rose to meet every challenge and successfully leveraged our commercial and operational strengths to capture robust demand for our diagnostic tests and instruments."